Loading…
Effect of tadalafil 5mg daily treatment on the ejaculatory times, lower urinary tract symptoms and erectile function in patients with erectile dysfunction
ABSTRACT Objective To investigate the effect of a 5mg daily tadalafil treatment on the ejaculation time, erectile function and lower urinary tract symptoms (LUTS) in patients with erectile dysfunction. Materials and Methods A total of 60 patients diagnosed with erectile dysfunction were retrospectiv...
Saved in:
Published in: | International Brazilian Journal of Urology 2017-03, Vol.43 (2), p.317-324 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c584t-91f291fe773a036eeb1d7ab13951bab39102d8c29fcd9ccd1eda510fe33712593 |
---|---|
cites | cdi_FETCH-LOGICAL-c584t-91f291fe773a036eeb1d7ab13951bab39102d8c29fcd9ccd1eda510fe33712593 |
container_end_page | 324 |
container_issue | 2 |
container_start_page | 317 |
container_title | International Brazilian Journal of Urology |
container_volume | 43 |
creator | Karabakan, Mehmet Keskin, Ercument Akdemir, Serkan Bozkurt, Aliseydi |
description | ABSTRACT Objective To investigate the effect of a 5mg daily tadalafil treatment on the ejaculation time, erectile function and lower urinary tract symptoms (LUTS) in patients with erectile dysfunction. Materials and Methods A total of 60 patients diagnosed with erectile dysfunction were retrospectively evaluated using the international index of erectile function questionnaire-5 (IIEF-5), intravaginal ejaculatory latency time (IELT) and international prostate symptoms scores (IPSS). After the patients were treated with 5mg tadalafil once a day for three months, their erection, ejaculation and LUTS were assessed again. The fasting levels of blood glucose, total testosterone, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and total cholesterol were measured. The independent-samples t-test was used to compare the pre- and post-treatment scores of the patients. Results The mean age of the 60 participants was 50.4±7.9 and the mean baseline serum total testosterone, total cholesterol, and fasting blood sugar were 444.6±178.6ng dL-1, 188.7±29.6mg/dL-1,104 (80-360) mg dL-1, respectively. The mean baseline scores were 2.2±1.4 min for IELT, 9.5±3.7 for IIEF-5 and 14.1±4.5 for IPSS. Following the three-month daily 5mg tadalafil treatment, the scores were found to be 3.4±1.9 min, 16.1±4.7, and 10.4±3.8 for IELT, IIEF and IPSS, respectively. When the baseline and post-treatment scores were compared, a statistically significant increase was observed in the IELTs and IIEF-5 values whereas there was a significant decrease in IPSS (p |
doi_str_mv | 10.1590/s1677-5538.ibju.2016.0376 |
format | article |
fullrecord | <record><control><sourceid>pubmedcentral_doaj_</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5433372</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_67c431d723b8447f894e4f2934370444</doaj_id><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_5433372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c584t-91f291fe773a036eeb1d7ab13951bab39102d8c29fcd9ccd1eda510fe33712593</originalsourceid><addsrcrecordid>eNpVkdFuFCEUhidGY2v1HfDeXWGAYbgxMU3VJk280WtyBg67bGaGDTA2-yo-bZmuVntBODn_z3c4-ZvmPaNbJjX9mFmn1EZK3m_DcFi2LWXdlnLVvWgun6SX_9UXzZucD5S2mir2urloVc-0kv1l8_vGe7SFRE8KOBjBh5HIaUcchPFESkIoE87VMJOyR4IHsMsIJaYqhgnzBzLGe0xkSWGGtZmg4vJpOpY4ZQKzI5jqhDAi8ctci0oKMzlCCZWbyX0o-38Wd8p_XW-bVx7GjO_-3FfNzy83P66_be6-f729_ny3sbIXZaOZb-tBpThQ3iEOzCkYGNeSDTBwzWjrettqb5221jF0IBn1yLlirdT8qrk9c12EgzmmMNU9TIRgHhsx7QykEuyIplNW8Ipv-dALoXyvBYo6nguuqBCisj6dWcdlmNDZumGC8Rn0uTKHvdnFX0YKXv_TVoA-A2yKOSf0T28ZNWv45jF8s6Zq1vDNGr5Zw-cPH5in2w</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Effect of tadalafil 5mg daily treatment on the ejaculatory times, lower urinary tract symptoms and erectile function in patients with erectile dysfunction</title><source>PMC (PubMed Central)</source><source>SciELO</source><creator>Karabakan, Mehmet ; Keskin, Ercument ; Akdemir, Serkan ; Bozkurt, Aliseydi</creator><creatorcontrib>Karabakan, Mehmet ; Keskin, Ercument ; Akdemir, Serkan ; Bozkurt, Aliseydi</creatorcontrib><description>ABSTRACT Objective To investigate the effect of a 5mg daily tadalafil treatment on the ejaculation time, erectile function and lower urinary tract symptoms (LUTS) in patients with erectile dysfunction. Materials and Methods A total of 60 patients diagnosed with erectile dysfunction were retrospectively evaluated using the international index of erectile function questionnaire-5 (IIEF-5), intravaginal ejaculatory latency time (IELT) and international prostate symptoms scores (IPSS). After the patients were treated with 5mg tadalafil once a day for three months, their erection, ejaculation and LUTS were assessed again. The fasting levels of blood glucose, total testosterone, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and total cholesterol were measured. The independent-samples t-test was used to compare the pre- and post-treatment scores of the patients. Results The mean age of the 60 participants was 50.4±7.9 and the mean baseline serum total testosterone, total cholesterol, and fasting blood sugar were 444.6±178.6ng dL-1, 188.7±29.6mg/dL-1,104 (80-360) mg dL-1, respectively. The mean baseline scores were 2.2±1.4 min for IELT, 9.5±3.7 for IIEF-5 and 14.1±4.5 for IPSS. Following the three-month daily 5mg tadalafil treatment, the scores were found to be 3.4±1.9 min, 16.1±4.7, and 10.4±3.8 for IELT, IIEF and IPSS, respectively. When the baseline and post-treatment scores were compared, a statistically significant increase was observed in the IELTs and IIEF-5 values whereas there was a significant decrease in IPSS (p<0.01). Conclusion A daily dose of 5mg tadalafil can be safely used in the treatment of erectile dysfunction and LUTS, that prolongs the ejaculatory latency time.</description><identifier>ISSN: 1677-5538</identifier><identifier>ISSN: 1677-6119</identifier><identifier>EISSN: 1677-5538</identifier><identifier>EISSN: 1677-6119</identifier><identifier>DOI: 10.1590/s1677-5538.ibju.2016.0376</identifier><identifier>PMID: 27819758</identifier><language>eng</language><publisher>Sociedade Brasileira de Urologia</publisher><subject>Ejaculation ; Erectile Dysfunction ; Original ; Tadalafil ; Therapeutics</subject><ispartof>International Brazilian Journal of Urology, 2017-03, Vol.43 (2), p.317-324</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c584t-91f291fe773a036eeb1d7ab13951bab39102d8c29fcd9ccd1eda510fe33712593</citedby><cites>FETCH-LOGICAL-c584t-91f291fe773a036eeb1d7ab13951bab39102d8c29fcd9ccd1eda510fe33712593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433372/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433372/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Karabakan, Mehmet</creatorcontrib><creatorcontrib>Keskin, Ercument</creatorcontrib><creatorcontrib>Akdemir, Serkan</creatorcontrib><creatorcontrib>Bozkurt, Aliseydi</creatorcontrib><title>Effect of tadalafil 5mg daily treatment on the ejaculatory times, lower urinary tract symptoms and erectile function in patients with erectile dysfunction</title><title>International Brazilian Journal of Urology</title><description>ABSTRACT Objective To investigate the effect of a 5mg daily tadalafil treatment on the ejaculation time, erectile function and lower urinary tract symptoms (LUTS) in patients with erectile dysfunction. Materials and Methods A total of 60 patients diagnosed with erectile dysfunction were retrospectively evaluated using the international index of erectile function questionnaire-5 (IIEF-5), intravaginal ejaculatory latency time (IELT) and international prostate symptoms scores (IPSS). After the patients were treated with 5mg tadalafil once a day for three months, their erection, ejaculation and LUTS were assessed again. The fasting levels of blood glucose, total testosterone, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and total cholesterol were measured. The independent-samples t-test was used to compare the pre- and post-treatment scores of the patients. Results The mean age of the 60 participants was 50.4±7.9 and the mean baseline serum total testosterone, total cholesterol, and fasting blood sugar were 444.6±178.6ng dL-1, 188.7±29.6mg/dL-1,104 (80-360) mg dL-1, respectively. The mean baseline scores were 2.2±1.4 min for IELT, 9.5±3.7 for IIEF-5 and 14.1±4.5 for IPSS. Following the three-month daily 5mg tadalafil treatment, the scores were found to be 3.4±1.9 min, 16.1±4.7, and 10.4±3.8 for IELT, IIEF and IPSS, respectively. When the baseline and post-treatment scores were compared, a statistically significant increase was observed in the IELTs and IIEF-5 values whereas there was a significant decrease in IPSS (p<0.01). Conclusion A daily dose of 5mg tadalafil can be safely used in the treatment of erectile dysfunction and LUTS, that prolongs the ejaculatory latency time.</description><subject>Ejaculation</subject><subject>Erectile Dysfunction</subject><subject>Original</subject><subject>Tadalafil</subject><subject>Therapeutics</subject><issn>1677-5538</issn><issn>1677-6119</issn><issn>1677-5538</issn><issn>1677-6119</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkdFuFCEUhidGY2v1HfDeXWGAYbgxMU3VJk280WtyBg67bGaGDTA2-yo-bZmuVntBODn_z3c4-ZvmPaNbJjX9mFmn1EZK3m_DcFi2LWXdlnLVvWgun6SX_9UXzZucD5S2mir2urloVc-0kv1l8_vGe7SFRE8KOBjBh5HIaUcchPFESkIoE87VMJOyR4IHsMsIJaYqhgnzBzLGe0xkSWGGtZmg4vJpOpY4ZQKzI5jqhDAi8ctci0oKMzlCCZWbyX0o-38Wd8p_XW-bVx7GjO_-3FfNzy83P66_be6-f729_ny3sbIXZaOZb-tBpThQ3iEOzCkYGNeSDTBwzWjrettqb5221jF0IBn1yLlirdT8qrk9c12EgzmmMNU9TIRgHhsx7QykEuyIplNW8Ipv-dALoXyvBYo6nguuqBCisj6dWcdlmNDZumGC8Rn0uTKHvdnFX0YKXv_TVoA-A2yKOSf0T28ZNWv45jF8s6Zq1vDNGr5Zw-cPH5in2w</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Karabakan, Mehmet</creator><creator>Keskin, Ercument</creator><creator>Akdemir, Serkan</creator><creator>Bozkurt, Aliseydi</creator><general>Sociedade Brasileira de Urologia</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20170301</creationdate><title>Effect of tadalafil 5mg daily treatment on the ejaculatory times, lower urinary tract symptoms and erectile function in patients with erectile dysfunction</title><author>Karabakan, Mehmet ; Keskin, Ercument ; Akdemir, Serkan ; Bozkurt, Aliseydi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c584t-91f291fe773a036eeb1d7ab13951bab39102d8c29fcd9ccd1eda510fe33712593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Ejaculation</topic><topic>Erectile Dysfunction</topic><topic>Original</topic><topic>Tadalafil</topic><topic>Therapeutics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karabakan, Mehmet</creatorcontrib><creatorcontrib>Keskin, Ercument</creatorcontrib><creatorcontrib>Akdemir, Serkan</creatorcontrib><creatorcontrib>Bozkurt, Aliseydi</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International Brazilian Journal of Urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karabakan, Mehmet</au><au>Keskin, Ercument</au><au>Akdemir, Serkan</au><au>Bozkurt, Aliseydi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of tadalafil 5mg daily treatment on the ejaculatory times, lower urinary tract symptoms and erectile function in patients with erectile dysfunction</atitle><jtitle>International Brazilian Journal of Urology</jtitle><date>2017-03-01</date><risdate>2017</risdate><volume>43</volume><issue>2</issue><spage>317</spage><epage>324</epage><pages>317-324</pages><issn>1677-5538</issn><issn>1677-6119</issn><eissn>1677-5538</eissn><eissn>1677-6119</eissn><abstract>ABSTRACT Objective To investigate the effect of a 5mg daily tadalafil treatment on the ejaculation time, erectile function and lower urinary tract symptoms (LUTS) in patients with erectile dysfunction. Materials and Methods A total of 60 patients diagnosed with erectile dysfunction were retrospectively evaluated using the international index of erectile function questionnaire-5 (IIEF-5), intravaginal ejaculatory latency time (IELT) and international prostate symptoms scores (IPSS). After the patients were treated with 5mg tadalafil once a day for three months, their erection, ejaculation and LUTS were assessed again. The fasting levels of blood glucose, total testosterone, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and total cholesterol were measured. The independent-samples t-test was used to compare the pre- and post-treatment scores of the patients. Results The mean age of the 60 participants was 50.4±7.9 and the mean baseline serum total testosterone, total cholesterol, and fasting blood sugar were 444.6±178.6ng dL-1, 188.7±29.6mg/dL-1,104 (80-360) mg dL-1, respectively. The mean baseline scores were 2.2±1.4 min for IELT, 9.5±3.7 for IIEF-5 and 14.1±4.5 for IPSS. Following the three-month daily 5mg tadalafil treatment, the scores were found to be 3.4±1.9 min, 16.1±4.7, and 10.4±3.8 for IELT, IIEF and IPSS, respectively. When the baseline and post-treatment scores were compared, a statistically significant increase was observed in the IELTs and IIEF-5 values whereas there was a significant decrease in IPSS (p<0.01). Conclusion A daily dose of 5mg tadalafil can be safely used in the treatment of erectile dysfunction and LUTS, that prolongs the ejaculatory latency time.</abstract><pub>Sociedade Brasileira de Urologia</pub><pmid>27819758</pmid><doi>10.1590/s1677-5538.ibju.2016.0376</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1677-5538 |
ispartof | International Brazilian Journal of Urology, 2017-03, Vol.43 (2), p.317-324 |
issn | 1677-5538 1677-6119 1677-5538 1677-6119 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5433372 |
source | PMC (PubMed Central); SciELO |
subjects | Ejaculation Erectile Dysfunction Original Tadalafil Therapeutics |
title | Effect of tadalafil 5mg daily treatment on the ejaculatory times, lower urinary tract symptoms and erectile function in patients with erectile dysfunction |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T16%3A13%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20tadalafil%205mg%20daily%20treatment%20on%20the%20ejaculatory%20times,%20lower%20urinary%20tract%20symptoms%20and%20erectile%20function%20in%20patients%20with%20erectile%20dysfunction&rft.jtitle=International%20Brazilian%20Journal%20of%20Urology&rft.au=Karabakan,%20Mehmet&rft.date=2017-03-01&rft.volume=43&rft.issue=2&rft.spage=317&rft.epage=324&rft.pages=317-324&rft.issn=1677-5538&rft.eissn=1677-5538&rft_id=info:doi/10.1590/s1677-5538.ibju.2016.0376&rft_dat=%3Cpubmedcentral_doaj_%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_5433372%3C/pubmedcentral_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c584t-91f291fe773a036eeb1d7ab13951bab39102d8c29fcd9ccd1eda510fe33712593%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/27819758&rfr_iscdi=true |